I can help, but pricing varies a lot by region, payer, and regimen. In the US and many other markets, list prices for PD‑1/PD‑L1 inhibitors (Keytruda and its rivals) are in the same general range, but the exact per‑dose and per‑cycle costs depend on dosing and negotiated discounts. Because rebates and patient assistance can make net prices quite different from list prices, it’s best to compare per-dose or per-cycle costs rather than sticker prices alone.
A couple of quick things to clarify so I can give you a concrete comparison:
- Which market/c country are you interested in (US, EU, UK, etc.)?
- Do you want price per dose, price per cycle, or total cost for a typical treatment course?
- Which rivals matter most to you (e.g., Opdivo/nivolumab, Tecentriq/atezolizumab, Libtayo/cemiplimab, Bavencio/avelumab, Imfinzi/durvalumab, etc.)?
If you’d like, I can:
- Provide a region-specific ballpark range for Keytruda and the main rivals, with notes on typical dosing schedules.
- Create a side-by-side comparison table (per-dose and per-cycle costs) using current list prices and common regimens, plus a note about discounts and patient access programs.
- Point you to sources where you can pull the latest price lists (manufacturer price lists, Red Book/price catalogs, payer dashboards, and Medicare/NGS reimbursement data).
Tell me your region and preferred format (per-dose, per-cycle, or per-course), and I’ll tailor a current, comparable snapshot.